Heron Therapeutics (HRTX) Convertible Debt (2011 - 2026)

Heron Therapeutics has reported Convertible Debt for 7 years, with the latest figure at $33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt fell 77.75% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $33.3 million (down 77.75% YoY), and the FY2025 full-year result was $32.7 million, down 78.13% from the prior year.
• Convertible Debt for Q1 2026 stood at $33.3 million, up from $32.7 million in the prior quarter.
• The five-year high for Convertible Debt was $149.8 million in Q1 2025, with the low at $32.2 million in Q3 2025.
• Historically, Convertible Debt has averaged $127.6 million across 5 years, with a median of $149.4 million in 2023.
• The largest YoY upside for Convertible Debt was 0.14% in 2025 against a maximum downside of 78.5% in 2025.
• Heron Therapeutics' Convertible Debt stood at $149.3 million in 2022, then increased by 0.14% to $149.5 million in 2023, then climbed by 0.14% to $149.7 million in 2024, then tumbled by 78.13% to $32.7 million in 2025, then climbed by 1.8% to $33.3 million in 2026.
• The last three Convertible Debt figures came in at $33.3 million (Q1 2026), $32.7 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.